Revelation Biosciences, Inc., (REVB): Price and Financial Metrics
GET POWR RATINGS... FREE!
REVB Stock Price Chart Interactive Chart >
REVB Price/Volume Stats
| Current price | $0.49 | 52-week high | $11.29 |
| Prev. close | $0.52 | 52-week low | $0.40 |
| Day low | $0.47 | Volume | 172,000 |
| Day high | $0.55 | Avg. volume | 1,542,088 |
| 50-day MA | $0.68 | Dividend yield | N/A |
| 200-day MA | $5.24 | Market Cap | 7.39M |
Revelation Biosciences, Inc., (REVB) Company Bio
Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
Latest REVB News From Around the Web
Below are the latest news stories about Revelation Biosciences Inc that investors may wish to consider to help them evaluate REVB as an investment opportunity.
Revelation Biosciences Inc. to Present at 2022 BIO CEO & Investor ConferenceSAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that its Chief Executive Officer James Rolke will present a corporate overview in-person at 10:45 a.m. EST on February 14, 2022 at the BIO CEO & Investor Conference, which is being held at the New York Marriott Ma |
Revelation Biosciences Raises $7.76 Million in Equity FinancingSAN DIEGO, Jan. 24, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that it has entered into a definitive agreement with a leading healthcare-focused institutional investor, pursuant to which the Company agreed to sell 1,293,126 shares of Common Stock (“Shares”) at a gross purchas |
Revelation Biosciences Inc. Announces First Group of Patients Dosed in Phase 2b Viral Challenge Study to Assess Efficacy of Intranasal REVTx-99 for the Prevention of H3N2 Influenza InfectionTop-line data anticipated in the second quarter of 2022SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, announced today that the first group of 15 patients have been enrolled and dosed in a Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx- |
Revelation Biosciences Inc. Announces First Patient Enrolled and Dosed in Phase 1b Clinical Study of REVTx-99 for the Treatment of Allergic RhinitisSAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced that the first patient has been enrolled and dosed in a Phase 1b clinical study to evaluate the potential utility of REVTx-99 for treating patients with allergic rhinitis and patients with chronic nasal congestion |
REPEAT -- Revelation Biosciences Inc. Announces Data Demonstrating REVTx-99 In Vitro Anti-Viral Activity Against SARS-CoV-2; Commencement of Trading as a Public Company-A greater than 50% reduction in SARS-CoV-2 Delta viral load was observed- -REVTx-99 was tested prior to infection in multiple standard in vitro anti-viral activity assay systems- -Previously announced SPAC merger closes, Revelation Biosciences, Inc. publicly listed on the NASDAQ under symbol REVB- -Revelation to host conference call and webcast at 4:30 p.m. Eastern Time on January 11, 2022. The conference call can be accessed by dialing 877-815-0146 for domestic callers and 631-625-3219 for int |
REVB Price Returns
| 1-mo | -7.91% |
| 3-mo | -79.24% |
| 6-mo | -95.19% |
| 1-year | N/A |
| 3-year | -98.24% |
| 5-year | -98.28% |
| YTD | -95.20% |
| 2021 | 1.49% |
| 2020 | -74.36% |
| 2019 | 37.54% |
| 2018 | 1.60% |
| 2017 | 59.83% |
Loading social stream, please wait...